White Paper

Understanding Potency In Gene Therapy Development

GettyImages-1221576332 cell therapy

Explore the importance of understanding potency in cell and gene therapy (CGT) development and the challenges in developing potency assays for CGT products. The FDA requires all approved biological products to undergo in vivo and/or in vitro tests to measure potency. The article discusses the necessity of measuring transgene expression levels in transduced cells throughout product development and at lot release. It also emphasizes the importance of precise and accurate in vitro assays in the development of treatments, stating that early and rigorous potency testing can lower failure rates and lead to more cost-effective treatments. Compliance with potency tests, FDA regulatory frameworks, and standard operating procedures can ensure product efficacy, purity, and safety.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene